Kensey Nash Company Profile

05:06 EDT 19th March 2018 | BioPortfolio

IntraLuminal Therapeutics, Inc. is a medical device company focused on both providing and developing products for the Interventional Cardiologist and Radiologist to cross and recanalize totally occluded arteries.
The company was co-founded by Dr. Geoffrey Hartzler, pioneer of multi-vessel percutaneous transluminal coronary intervention (PTCI) and a recognized leader in the area of interventional cardiology. Incorporated in October 1997, the company is located in Carlsbad, California.


735 Pennsylvania Drive
United States of America


Phone: (484) 713-2100
Fax: (484) 713-2900

News Articles [201 Associated News Articles listed on BioPortfolio]

The Race To Find A Treatment For NASH

Although there are a number of investigational NASH therapies in various stages of development, there is no approved drug yet for this silent killer. However, the fact that the race to develop an effe...

Emerging pharmacologic approach may inhibit NASH

Treating a liver disease called NASH (non-alcoholic steatohepatitis), which affects 10 to 15 percent of obese individuals with type-2 diabetes worldwide, is difficult. But now scientists believe they ...

[Comment] FGF-19 agonism for NASH: a short study of a long disease

Non-alcoholic steatohepatitis (NASH) has emerged as the most common cause of liver disease worldwide and is on a trajectory to become the most common indication for liver transplantation.1,2 Interest ...

Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements

Privately held Cirius and NGM and big pharma Bristol-Myers Squibb are in Phase II for NASH with programs also working...   

Boehringer Ingelheim Partners with Target PharmaSolutions to Progress NASH Research

CHAPEL HILL, N.C., Oct. 19, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Boehringer Ingelheim International GmbH has entered ...

The NASH Education Program™: Key Insights from the First US Survey Commissioned by the NASH ...


Bristol-Myers Squibb Extends Partnership with Target PharmaSolutions for TARGET-NASH

CHAPEL HILL, N.C, Oct. 12, 2017 /PRNewswire/ — TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic...

Galectin drops 40% on negative NASH result

The biotech's stock took a major hit when its NASH drug didn't work in the overall study population.

PubMed Articles [108 Associated PubMed Articles listed on BioPortfolio]

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model.

The incidence of nonalcoholic steatohepatitis (NASH) is increasing. The pathophysiological mechanisms of NASH and the sequence of events leading to hepatic fibrosis are incompletely understood. The ai...

Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England.

There are no national studies evaluating the epidemiology of non-alcoholic steatohepatitis (NASH) in England. NASH is becoming an increasingly important health issue given the inexorable rise in obesi...

The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement.

Non-alcoholic fatty liver disease (NAFLD) is frequently associated with obesity and overweight. It has a broad spectrum of clinical and histological presentations, such as steatosis, inflammation (kno...

Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects.

Bile acids (BA) are signalling molecules controlling energy homeostasis which can be both toxic and protective for the liver. BA alterations have been reported in obesity, insulin resistance (IR) and ...

The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom.

Nonalcoholic fatty liver disease (NAFLD) is a common liver disorder that can be divided into benign steatosis or nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). Elastography a...

Clinical Trials [131 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis (BEAT-NASH)

Obesity is an epidemic in the US. With progression of obesity, Nonalcoholic steatohepatitis (NASH) has been a growing public health issue. Presently there is no cure for NASH.Prevention of...

Companies [24 Associated Companies listed on BioPortfolio]

Kensey Nash Corp.

Kensey Nash Corporation

Kensey Nash

IntraLuminal Therapeutics, Inc. is a medical device company focused on both providing and developing products for the Interventional Cardiologist and Radiologist to cross and recanalize totally occlud...

Nash Finch Company

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

More Information about "Kensey Nash" on BioPortfolio

We have published hundreds of Kensey Nash news stories on BioPortfolio along with dozens of Kensey Nash Clinical Trials and PubMed Articles about Kensey Nash for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kensey Nash Companies in our database. You can also find out about relevant Kensey Nash Drugs and Medications on this site too.

Quick Search


Relevant Topics

Medical Devices
The role of medical devices in healthcare is essential.  The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare.  Covering a wide range of products, from simple bandages to the...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Corporate Database Quicklinks

Searches Linking to this Company Record